Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels
Insights
Monitoring valproic acid levels in epileptic children showed that higher plasma concentrations correlated with treatment resistance. A therapeutic range of 40-90 micrograms/ml is suggested for optimal seizure control.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Epilepsy management in children requires effective antiepileptic drugs.
- Valproic acid is a widely used antiepileptic medication.
- Understanding optimal therapeutic ranges is crucial for patient outcomes.
Purpose of the Study:
- To monitor plasma valproic acid levels in epileptic children.
- To correlate plasma concentrations with seizure control and treatment resistance.
- To evaluate the efficacy of sodium valproate in different epilepsy types and combinations.
Main Methods:
- Prospective monitoring of plasma valproic acid levels over two years in 90 epileptic children.
- Analysis of seizure control in patients on monotherapy and combination therapy.
- Statistical comparison of plasma levels between controlled and uncontrolled patient groups.
Main Results:
- 82% of children on sodium valproate monotherapy achieved seizure control at a mean plasma level of 65.1 +/- 20.3 micrograms/ml.
- Higher plasma levels (91.7 +/- 35.2 micrograms/ml) were associated with treatment resistance (p = 0.008).
- Side effects, including appetite increase and gastrointestinal issues, were observed in 21% of patients, often with levels above 70 micrograms/ml.
Conclusions:
- Sodium valproate appears effective for absences, tonic-clonic, and partial seizures.
- A therapeutic plasma concentration range of 40-90 micrograms/ml is proposed for sodium valproate in children.
- Treatment resistance may be linked to plasma levels outside the proposed therapeutic range.
Abstract:
Plasma levels of valproic acid were monitored for two years in 90 epileptic children. From 34 patients receiving sodium valproate as monotherapy, complete seizure control could be achieved in 28 children (82%) with a mean (+/- SD) plasma level of 65.1 +/- 20.3 micrograms/ml. In 6 patients (18%) seizures recurred. Since their plasma levels were significantly (p = 0.008) higher (91.7 +/- 35.2 micrograms/ml) than in the controlled patients, their disorder might be regraded as resistant to therapy with sodium valproate. The drug seems to be effective in patients with absences, tonic-clonic seizures and partial epilepsy. The most common combination of anticonvulsants administered was valproate/phenobarbital (n = 22). In 14 children of this group (64%) seizures were completely controlled with plasma levels of 54.6 +/- 26.5 micrograms/ml. In the 5 uncontrolled patients (23%) valproate concentrations were lower (33.8 +/- 28.2 micrograms/ml; p = 0.08). 20 children were treated with more than two anticonvulsants. This population probably represents the most severe cases. Therefore it was not surprising that only 7 patients (35%) exhibited complete seizure control with valproate plasma concentrations of 63.1 +/- 51.9 micrograms/ml. In the uncontrolled patients these levels were slightly lower (43.8 +/- 24.8 micrograms/ml). Side effects were observed in 7 patients (21%) receiving sodium valproate alone. Most common effects were increase in appetite (n = 4), and gastrointestinal disturbances (n = 2). Additionally, one patient complained about transient hair loss and one felt tired. In most cases their plasma concentrations were above 70 micrograms/ml. A therapeutic range of 40--90 micrograms/ml is postulated.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion


